Study of PRO 140 SC as Single Agent Maintenance Therapy in Virally Suppressed Subjects With CCR5-tropic HIV-1 Infection

What is the purpose of this trial?

This study is a Phase 2b/3, multi-center study designed to evaluate the efficacy, safety, and tolerability of the strategy of shifting clinically stable patients receiving suppressive combination antiretroviral therapy to PRO 140 monotherapy and maintaining viral suppression for 48 weeks following study entry.

Consenting patients will be shifted from combination antiretroviral regimen to weekly PRO 140 monotherapy for 48 weeks during the Treatment Phase with the one week overlap of existing retroviral regimen and PRO 140 at the beginning of the study treatment and also one week overlap at the end of the treatment in subjects who do not experience virologic failure.


Participation Guidelines

Ages: 18 years and older

Gender: Both


CytoDyn, Inc.

Start Date: 09/05/2017

End Date: 12/31/2017

Last Updated: 02/22/2018

Study HIC#: 2000020372

Get Involved

For more information about this study, contact:
Laurie J Andrews
+1 203-785-3557
laurie.andrews@yale.edu

If you would prefer to contact a member of the Help us Discover team about this trial and other similar trials, please email helpusdiscover@yale.edu or call 1-877-978-8348.

Trial Image

Investigators

Onyema Eberechukwu Ogbuagu

Principal Investigator

Sub-Investigators